IDiyas

For the Inventor, By the Inventor

Santa Fe, NM, United States of America

Simon H Stertzer

USPTO Granted Patents = 11 

Average Co-Inventor Count = 5.7

ph-index = 6

Forward Citations = 800(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2002 - 2011)
  • San Francisco, CA (US) (2008 - 2015)
  • San Carlos, CA (US) (2015)
  • Santa Fe, NM (US) (2013 - 2016)

Company Filing History:

goldMedal11 out of 57 
 
Biocardia, Inc.
 patents

Years Active: 2002-2016

Loading Chart...
11 patents (USPTO):Explore Patents
1. 9517199 - Treatment for chronic myocardial infarct (2016-12-13),
2. 9504642 - Treatment for chronic myocardial infarct (2016-11-29),
3. 9078994 - Method of accessing a contralateral femoral artery of a patient (2015-07-14),
4. 9022977 - Method of accessing a renal artery of a patient (2015-05-05),
5. 9017284 - Method of implanting a PFO occluder in a patient (2015-04-28),
6. 9011373 - Method of accessing a carotid artery of a patient (2015-04-21),
7. 8939960 - Steerable guide catheters and methods for their use (2015-01-27),
8. 8496926 - Treatment for chronic myocardial infarction (2013-07-30),
9. 8027740 - Drug delivery catheters that attach to tissue and methods for their use (2011-09-27),
10. 7402151 - Steerable guide catheters and methods for their use (2008-07-22),
11. 6416510 - Drug delivery catheters that attach to tissue and methods for their use (2002-07-09),

Title: Simon H Stertzer: Innovator in Cardiac Treatment

Introduction

Simon H Stertzer is a prominent inventor based in Santa Fe, NM (US), known for his significant contributions to the field of cardiac treatment. With a total of 11 patents to his name, he has made remarkable advancements in medical technology, particularly in the treatment of chronic myocardial infarction.

Latest Patents

One of his latest patents involves a method for treating chronic post-myocardial infarction. This innovative approach utilizes helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in patients who have experienced chronic myocardial infarction. The treatment has been shown to be safe and effective, improving ejection fraction (EF) in patients.

Career Highlights

Simon H Stertzer has established himself as a key figure in the medical field through his work at Biocardia, Inc. His dedication to improving patient outcomes through innovative treatments has garnered attention and respect within the medical community.

Collaborations

Throughout his career, Simon has collaborated with notable professionals, including Peter A Altman and Daniel C Rosenman. These partnerships have contributed to the development of groundbreaking medical solutions.

Conclusion

In summary, Simon H Stertzer is a distinguished inventor whose work in cardiac treatment has the potential to transform patient care. His innovative methods and dedication to research continue to pave the way for advancements in medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…